Other analysts have also issued research reports about the stock. Stifel Nicolaus began coverage on shares of Roche in a research note on Monday, February 28th. They issued a buy rating for the company. JPMorgan Chase & Co. dropped their target price on Roche from CHF 390 to CHF 370 and set a neutral rating on the stock in a report on Friday, March 11th. Zacks Investment Research raised shares of Roche from a hold rating to a strong-buy rating and set a $58.00 price objective on the stock in a report on Wednesday, January 19th. Finally, Citigroup started coverage on shares of Roche in a research report on Wednesday, December 22nd. They issued a buy rating for the company. Five investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Roche presently has an average rating of Buy and an average target price of $292.67.
Roche stock opened at $51.63 on Thursday. The stock’s 50 day moving average is $48.60 and its 200 day moving average is $49.12. Roche has a one year low of $40.59 and a one year high of $53.86. The company has a quick ratio of 0.73, a current ratio of 0.93 and a debt-to-equity ratio of 0.57.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Horizon Advisors Inc. raised its stake in shares of Roche by 76.4% during the fourth quarter. First Horizon Advisors Inc. now owns 709 shares of the company’s stock valued at $35,000 after acquiring an additional 307 shares during the last quarter. Elmwood Wealth Management Inc. bought a new position in shares of Roche in the 4th quarter worth approximately $128,000. Roanoke Asset Management Corp NY purchased a new position in Roche during the fourth quarter valued at $207,000. Enterprise Financial Services Corp bought a new position in shares of Roche in the 4th quarter worth about $255,000. Finally, Toroso Investments LLC bought a new position in shares of Roche in the 3rd quarter worth about $232,000. 0.18% of the stock is owned by institutional investors.
About Roche (Get Rating)
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation.
- Get a free copy of the StockNews.com research report on Roche (RHHBY)
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
- Array Technologies Stock Giving Another Ground Floor Entry
- 3 Undervalued S&P 500 Stocks to Buy Now
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.